1. Chung TDY, Terry DB, Smith LH (2004) In vitro and in vivo assessment of ADME and PK properties during lead selection and lead optimization—guidelines, benchmarks and rules of thumb. In: Markossian S, Grossman A, Brimacombe K, Arkin M, Auld D, Austin C, Baell J, Chung TDY, Coussens NP, Dahlin JL, Devanarayan V, Foley TL, Glicksman M, Haas JV, Hall MD, Hoare S, Inglese J, Iversen PW, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Sittampalam GS, Tarselli M, Trask OJ Jr, Wang Y, Weidner JR, Wildey MJ, Wilson K, Xia M, Xu X (eds) Assay guidance manual. Bethesda
2. Clark DE, Grootenhuis PD (2002) Progress in computational methods for the prediction of ADMET properties. Curr Opin Drug Discov Devel 5(3):382–390
3. Dearden JC (2007) In silico prediction of ADMET properties: how far have we come? Expert Opin Drug Metab Toxicol 3(5):635–639
4. Göller AH, Kuhnke L, Montanari F, Bonin A, Schneckener S, ter Laak A, Wichard J, Lobell M, Hillisch A (2020) Bayer’s in silico ADMET platform: a journey of machine learning over the past two decades. Drug Discov Today 25(9):1702–1709
5. Göller AH, Kuhnke L, ter Laak A, Meier K, Hillisch A (2022) Machine learning applied to the modeling of pharmacological and ADMET absorption, distribution, metabolism, excretion and toxicity (ADMET) endpoints. In: Heifetz A (ed) Artificial intelligence in drug design. New York, Springer, pp 61–101